Abstract:
PROBLEM TO BE SOLVED: To provide RNA interference for inhibition of connective tissue growth factor mRNA expression in ocular disorders involving CTGF expression.SOLUTION: Ocular disorders involving aberrant CTGF expression include glaucoma, macular degeneration, diabetic retinopathy, choroidal neovascularization, proliferative vitreoretinopathy and wound healing. Such disorders are treated by administering interfering RNAs. There is provided a method of attenuating expression of connective tissue growth factor mRNA in an eye of a subject. The method comprises administering to the eye of the subject a composition comprising an effective amount of interfering RNA such as adouble-stranded (ds) siRNA or single-stranded (ss) siRNA having a lentgh of 19 to 49 nucleotides and a pharmaceutically acceptable carrier.
Abstract:
PROBLEM TO BE SOLVED: To provide a reliable ultrasonic hand piece which vibrates in both of a vertical maneuver and a twisting maneuver simultaneously or separately without using a piezoelectric crystal.SOLUTION: The ultrasonic handpiece includes a magnetorestrictive stack 210, a horn 220 for ultrasonic wave which is attached to the stack while including a plurality of slits 260, and an electric coil 250 which surrounds the stack adapted for receiving a drive signal. The plurality of slits have enough size and space to generate a twisting motion in the horn in response to the drive signal with a first frequency and generate a vertical motion in the horn in response to the drive signal with a second frequency.
Abstract:
PROBLEM TO BE SOLVED: To present an easy and reliable irrigation/aspiration system that reduces surge of fluid.SOLUTION: A surgical system has irrigation and aspiration lines. Both lines have different compliance or stiffness. The irrigation line has a compliance more reliable than the aspiration line.
Abstract:
PROBLEM TO BE SOLVED: To provide methods for diagnosing glaucoma and compositions for treating glaucoma. SOLUTION: There are provided a method for treating glaucoma which method comprises a step of administering a therapeutically effective amount of a composition to a patient requiring treatment of glaucoma wherein the composition comprises a factor interacting with a gene encoding serum amyloid A protein (SAA), and the interaction modulates the expression of SAA, and a method for treating glaucoma which method comprises a step of administering a therapeutically effective amount of a composition to a patient requiring treatment of glaucoma wherein the composition comprises a factor inhibiting the interaction of serum amyloid A protein (SAA) with a receptor thereof. COPYRIGHT: (C)2011,JPO&INPIT
Abstract:
PROBLEM TO BE SOLVED: To treat disorders of the outer retina resulting from acute or chronic degenerative conditions or diseases of the eye. SOLUTION: There are provided compositions and methods for treating disorders of the outer retina using compounds with 5-HT 1A agonist activity. The invention is directed to 5-HT 1A agonist which is discovered to be useful in treating disorders of the outer retina, particularly: AMD; RP and other forms of heredodegenerative retinal disease; retinal detachment and tears; macular pucker; ischemia affecting the outer retina; diabetic retinopathy; damage associated with laser therapy (grid, focal, and panretinal) including photodynamic therapy (PDT); trauma; surgical (retinal translocation, subretinal surgery, or vitrectomy); retinopathy or light-induced iatrogenic retinopathy; and preservation of retinal transplants. COPYRIGHT: (C)2011,JPO&INPIT
Abstract:
PROBLEM TO BE SOLVED: To reduce IOP (intraocular pressure) and/or to provide neuroprotection to optic disk and/or retinal ganglion cells through a pathogenic pathway. SOLUTION: A method for reducing IOP and providing neuroprotection to a patient in need, who needs the neuroprotection through IOP reduction, by administering a therapeutically effective amount of at least one non-nucleotide agent or non-protein agent that inhibits expression and/or signal transmission of connective tissue growth factor (CTGF) is provided. A method for reducing IOP of a patient requiring IOP reduction is also provided, including a step of administering the therapeutically effective amount of a composition comprising at least one non-nucleotide agent or non-protein agent that inhibits expression, signal transmission or biological function of CTGF, and a pharmaceutically acceptable carrier. COPYRIGHT: (C)2011,JPO&INPIT
Abstract:
PROBLEM TO BE SOLVED: To provide an aerodynamic module for supplying power to a vitrectomy apparatus, attaining the high speed operation of the vitrectomy apparatus with the minimum number of components. SOLUTION: A system for supplying aerodynamic power to the vitrectomy apparatus includes the first (A) and second (B) output ports, an output valve (210), an exhaust valve (205), and three manifolds. The output valve supplies compressed gas to the first and second output ports alternately, and the exhaust valve (205) supplies pressurized gas to the output valve. Two manifolds fluidly connect the output valve to the first and second output ports, and the third manifold (250) fluidly connects the exhaust valve to the output valve. When the exhaust valve supplies pressurized gas to the output valve, the output valve supplies the pressurized gas to the first and second output ports alternately at high speed to supply power to the apparatus. COPYRIGHT: (C)2011,JPO&INPIT
Abstract:
PROBLEM TO BE SOLVED: To provide a method of priming a surgical system by which residual entrained air inside a surgical instrument can be securely removed. SOLUTION: The method of priming a surgical system includes a step to pull a very high vacuum and then cycling fluid through the system as a fluid pulse. These steps can be repeated a number of times to help ensure that residual entrained air is removed from the system. COPYRIGHT: (C)2009,JPO&INPIT
Abstract:
PROBLEM TO BE SOLVED: To provide a method and a kit for diagnosing and treating glaucoma. SOLUTION: The present invention provides a method for diagnosing glaucoma by detecting the change in gene expression of the bone morphogenic protein (BMP) forming family member genes in a sample obtained from cells or body fluid. This method preferably comprises the following steps: the step wherein a tissue or liquid sample is obtained from a patient suspected to have glaucoma, the step wherein DNA is extracted from the sample, the step wherein a plurality of PCR primers are obtained, the step wherein the regions of the extracted DNA are amplified by using the primers to obtain the PCR products, and the step wherein the difference between the DNA sequence of the extracted and amplified product and the sequence of the primer is identified. COPYRIGHT: (C)2009,JPO&INPIT
Abstract:
PROBLEM TO BE SOLVED: To provide a reliable ultrasonic handpiece vibrating in longitudinal movement and torsional movement simultaneously or separately. SOLUTION: A method employing a handpiece having at least a set of piezoelectric elements polarized to produce a longitudinal movement when excited at the relevant resonant frequency. The piezoelectric crystals are connected to an ultrasonic horn to which a cutting tip 20 is attached. The horn and/or the cutting tip contains a plurality of diagonal slits or grooves. The slits or grooves produce optimized torsional movement in the cutting tip when the piezoelectric crystals are excited at a second resonant frequency. When in torsional mode, material may clog the cutting tip. The present method includes the step of providing a pulse of longitudinal movement of the cutting tip when clogging is detected. COPYRIGHT: (C)2009,JPO&INPIT